At the time of writing, Mirum Pharmaceuticals Inc [MIRM] stock is trading at $44.00, up 6.49%. An important factor to consider is whether the stock is rising or falling in short-term value. The MIRM shares have gain 2.80% over the last week, with a monthly amount drifted -0.23%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mirum Pharmaceuticals Inc [NASDAQ: MIRM] stock has seen the most recent analyst activity on April 17, 2024, when Stifel initiated its Buy rating and assigned the stock a price target of $48. Previously, H.C. Wainwright reaffirmed its Buy rating on December 18, 2023, and dropped its price target to $58. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $60 on November 13, 2023. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $50 as its price target on October 24, 2023. In a note dated September 20, 2023, JMP Securities initiated an Mkt Outperform rating and provided a target price of $70 on this stock.
For the past year, the stock price of Mirum Pharmaceuticals Inc fluctuated between $23.14 and $48.89. Currently, Wall Street analysts expect the stock to reach $57 within the next 12 months. Mirum Pharmaceuticals Inc [NASDAQ: MIRM] shares were valued at $44.00 at the most recent close of the market. An investor can expect a potential return of 29.55% based on the average MIRM price forecast.
Analyzing the MIRM fundamentals
According to Mirum Pharmaceuticals Inc [NASDAQ:MIRM], the company’s sales were 307.03M for trailing twelve months, which represents an 89.37% jump. Gross Profit Margin for this corporation currently stands at 0.73% with Operating Profit Margin at -0.3%, Pretax Profit Margin comes in at -0.31%, and Net Profit Margin reading is -0.32%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -0.41 and Total Capital is -0.17. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 41.77 points at the first support level, and at 39.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 45.17, and for the 2nd resistance point, it is at 46.33.
Ratios To Look Out For
It is important to note that Mirum Pharmaceuticals Inc [NASDAQ:MIRM] has a current ratio of 3.34. On the other hand, the Quick Ratio is 3.15, and the Cash Ratio is 1.93. Considering the valuation of this stock, the price to sales ratio is 6.88, the price to book ratio is 9.10.
Transactions by insiders
Recent insider trading involved Radovich Peter, PRESIDENT AND COO, that happened on Jan 07 ’25 when 1998.0 shares were sold. CHIEF EXECUTIVE OFFICER, Peetz Christopher completed a deal on Jan 07 ’25 to sell 7489.0 shares. Meanwhile, SVP, GLOBAL CONTROLLER Howe Jolanda sold 750.0 shares on Jan 07 ’25.
